Adverum Biotechnologies, Inc. (ADVM) analyst actions
Rating and price-target actions on ADVM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ADVM overview →
3 measured ADVM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Reach Out | Press release | +0.64% | -2.04% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out | Press release | +1.39% | +1.74% | |
| Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD | Press release | -4.39% | +3.66% |
Keep exploring
More ADVM: earnings → · SEC filings → · ADVM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Syros Pharmaceuticals, Inc. (SYRS) | 307 | +0.51% | 55% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 306 | +0.04% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.